Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All iota‑carrageenan studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Morokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post market surveillance data show that iota-carrageenan is well-tolerated with very low reported adverse events.
15 preclinical studies support the efficacy of iota-carrageenan for COVID-19:
Morokutti-Kurz et al., 17 Feb 2021, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIota-carragee..All
Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
Martina Morokutti-Kurz, Maria Fröba, Philipp Graf, Maximilian Große, Andreas Grassauer, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer
PLOS ONE, doi:10.1371/journal.pone.0237480
In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC 50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iotacarrageenan against various Rhino-and endemic Coronaviruses showed similar IC 50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.
Supporting information S1 Author Contributions Conceptualization: Martina Morokutti-Kurz, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Data curation: Martina Morokutti-Kurz, Maria Fro ¨ba, Philipp Graf, Maximilian Große, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer. Formal analysis: Martina Morokutti-Kurz, Maria Fro ¨ba, Philipp Graf, Maximilian Große, Andreas Grassauer, Janina Auth. Funding acquisition: Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Investigation: Maria Fro ¨ba, Philipp Graf, Maximilian Große, Janina Auth. Methodology: Martina Morokutti-Kurz, Maria Fro ¨ba, Janina Auth, Ulrich Schubert. Project administration: Janina Auth, Eva Prieschl-Grassauer. Resources: Andreas Grassauer, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer. Software: Eva Prieschl-Grassauer. Supervision: Ulrich Schubert. Validation: Eva Prieschl-Grassauer. Visualization: Eva Prieschl-Grassauer. Writing -original draft: Martina Morokutti-Kurz, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer. Writing -review & editing: Martina Morokutti-Kurz, Maria Fro ¨ba, Maximilian Große, Andreas Grassauer, Ulrich Schubert, Eva Prieschl-Grassauer.
References
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill, doi:10.2807/1560-7917.ES.2020.25.3.2000045
Dogan, Kozhaya, Placek, Gunter, Yigit et al., Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19, medRxiv, doi:10.1101/2020.07.07.20148106
Eccles, Iota-Carrageenan as an Antiviral Treatment for the Common Cold, The Open Virology Journal
Eccles, Meier, Jawad, Weinmu ¨llner R, Grassauer et al., Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold, Respir Res, doi:10.1186/1465-9921-11-108
Eccles, Winther, Johnston, Robinson, Trampisch et al., Efficacy and safety of iotacarrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial, Respir Res, doi:10.1186/s12931-015-0281-8
Fazekas, Eickhoff, Pruckner, Vollnhofer, Fischmeister et al., Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold, BMC Complement Altern Med, doi:10.1186/1472-6882-12-147
Gates, Responding to Covid-19-A Once-in-a-Century Pandemic, N Engl J Med, doi:10.1056/NEJMp2003762
Grassauer, Weinmu ¨llner R, Meier, Pretsch, Prieschl-Grassauer et al., Iota-Carrageenan is a potent inhibitor of rhinovirus infection, Virol J, doi:10.1186/1743-422X-5-107
Große, Ruetalo, Businger, Rheber, Setz et al., Evidence That Quinine Exhibits Antiviral Activity against SARS-CoV-2 Infection In Vitro, Preprints
Hoffmann, Kleine-Weber, Schroeder, Kru ¨ger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Koenighofer, Lion, Bodenteich, Prieschl-Grassauer, Grassauer et al., Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials, Multidiscip Respir Med, doi:10.1186/2049-6958-9-57
Leibbrandt, Meier, Ko ¨nig-Schuster, Weinmu ¨llner R, Kalthoff et al., Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection, PLoS One, doi:10.1371/journal.pone.0014320
Long, Tang, Shi, Li, Deng et al., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med, doi:10.1038/s41591-020-0965-6
Ludwig, Enzenhofer, Schneider, Rauch, Bodenteich et al., Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial, Respir Res, doi:10.1186/1465-9921-14-124
Mcintosh, Dees, Becker, Kapikian, Chanock, Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease, Proc Natl Acad Sci U.S.A, doi:10.1073/pnas.57.4.933
Morokutti-Kurz, Konig-Schuster, Koller, Graf, Graf et al., The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model 4944, PLoS ONE, doi:10.1371/journal.pone.0128794
Perlman, Another Decade, Another Coronavirus, N Engl J Med, doi:10.1056/NEJMe2001126
Reed, Muench, A simple method of estimating fifty percent endpoints, Am J Hyg
Wu, Zhao, Yu, Chen, Song, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3
Zhu, Zhang, Li, Yang, Song, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
{ 'indexed': {'date-parts': [[2024, 5, 8]], 'date-time': '2024-05-08T13:53:49Z', 'timestamp': 1715176429581}, 'reference-count': 20, 'publisher': 'Public Library of Science (PLoS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T00:00:00Z', 'timestamp': 1613520000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100004955', 'name': 'Österreichische Forschungsförderungsgesellschaft', 'doi-asserted-by': 'publisher', 'award': ['880687']}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'abstract': '<jats:p>In the absence of a vaccine and other effective prophylactic or therapeutic ' 'countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) ' 'remains a significant public health threat. Attachment and entry of coronaviruses including ' 'SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan ' 'can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent ' 'manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with ' 'an IC<jats:sub>50</jats:sub> value of 2.6 μg/ml iota-carrageenan. Experiments with patient ' 'isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. ' 'In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed ' 'similar IC<jats:sub>50</jats:sub> values and translated readily into clinical effectiveness ' 'when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and ' 'duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our ' 'in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 ' 'suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or ' 'treatment for SARS-CoV-2 infections.</jats:p>', 'DOI': '10.1371/journal.pone.0237480', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T18:34:13Z', 'timestamp': 1613586853000}, 'page': 'e0237480', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 74, 'title': 'Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro', 'prefix': '10.1371', 'volume': '16', 'author': [ {'given': 'Martina', 'family': 'Morokutti-Kurz', 'sequence': 'first', 'affiliation': []}, {'given': 'Maria', 'family': 'Fröba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philipp', 'family': 'Graf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maximilian', 'family': 'Große', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andreas', 'family': 'Grassauer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Janina', 'family': 'Auth', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ulrich', 'family': 'Schubert', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eva', 'family': 'Prieschl-Grassauer', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2021, 2, 17]]}, 'reference': [ { 'key': 'pone.0237480.ref001', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', 'volume': '382', 'author': 'N Zhu', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref002', 'doi-asserted-by': 'crossref', 'first-page': '265', 'DOI': '10.1038/s41586-020-2008-3', 'article-title': 'A new coronavirus associated with human respiratory disease in China', 'volume': '579', 'author': 'F Wu', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'pone.0237480.ref003', 'doi-asserted-by': 'crossref', 'first-page': '760', 'DOI': '10.1056/NEJMe2001126', 'article-title': 'Another Decade, Another Coronavirus', 'volume': '382', 'author': 'S. Perlman', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref004', 'doi-asserted-by': 'crossref', 'first-page': '1677', 'DOI': '10.1056/NEJMp2003762', 'article-title': 'Responding to Covid-19—A Once-in-a-Century Pandemic', 'volume': '382', 'author': 'B. Gates', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'pone.0237480.ref005', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a ' 'Clinically Proven Protease Inhibitor', 'volume': '181', 'author': 'M Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'issue': '14', 'key': 'pone.0237480.ref006', 'doi-asserted-by': 'crossref', 'first-page': '9', 'DOI': '10.2174/1874357902014010009', 'article-title': 'Iota-Carrageenan as an Antiviral Treatment for the Common Cold', 'volume': '2020', 'author': 'R. Eccles', 'year': '2020', 'journal-title': 'The Open Virology Journal'}, { 'key': 'pone.0237480.ref007', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/1743-422X-5-107', 'article-title': 'Iota-Carrageenan is a potent inhibitor of rhinovirus infection', 'volume': '5', 'author': 'A Grassauer', 'year': '2008', 'journal-title': 'Virol J'}, { 'key': 'pone.0237480.ref008', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0014320', 'article-title': 'Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection', 'volume': '5', 'author': 'A Leibbrandt', 'year': '2010', 'journal-title': 'PLoS One'}, { 'key': 'pone.0237480.ref009', 'doi-asserted-by': 'crossref', 'first-page': 'e0128794', 'DOI': '10.1371/journal.pone.0128794', 'article-title': 'The Intranasal Application of Zanamivir and Carrageenan Is ' 'Synergistically Active against Influenza A Virus in the Murine Model ' '4944', 'volume': '10', 'author': 'M Morokutti-Kurz', 'year': '2015', 'journal-title': 'PLoS ONE'}, { 'key': 'pone.0237480.ref010', 'doi-asserted-by': 'crossref', 'first-page': '108', 'DOI': '10.1186/1465-9921-11-108', 'article-title': 'Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a ' 'randomized, double-blind, placebo-controlled exploratory study in ' 'volunteers with early symptoms of the common cold', 'volume': '11', 'author': 'R Eccles', 'year': '2010', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref011', 'doi-asserted-by': 'crossref', 'first-page': '147', 'DOI': '10.1186/1472-6882-12-147', 'article-title': 'Lessons learned from a double-blind randomised placebo-controlled study ' 'with a iota-carrageenan nasal spray as medical device in children with ' 'acute symptoms of common cold', 'volume': '12', 'author': 'T Fazekas', 'year': '2012', 'journal-title': 'BMC Complement Altern Med'}, { 'key': 'pone.0237480.ref012', 'doi-asserted-by': 'crossref', 'first-page': '57', 'DOI': '10.1186/2049-6958-9-57', 'article-title': 'Carrageenan nasal spray in virus confirmed common cold: individual ' 'patient data analysis of two randomized controlled trials', 'volume': '9', 'author': 'M Koenighofer', 'year': '2014', 'journal-title': 'Multidiscip Respir Med'}, { 'key': 'pone.0237480.ref013', 'doi-asserted-by': 'crossref', 'first-page': '124', 'DOI': '10.1186/1465-9921-14-124', 'article-title': 'Efficacy of a carrageenan nasal spray in patients with common cold: a ' 'randomized controlled trial', 'volume': '14', 'author': 'M Ludwig', 'year': '2013', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref014', 'doi-asserted-by': 'crossref', 'first-page': '121', 'DOI': '10.1186/s12931-015-0281-8', 'article-title': 'Efficacy and safety of iota-carrageenan nasal spray versus placebo in ' 'early treatment of the common cold in adults: the ICICC trial', 'volume': '16', 'author': 'R Eccles', 'year': '2015', 'journal-title': 'Respir Res'}, { 'key': 'pone.0237480.ref015', 'first-page': '2020070102', 'article-title': 'Evidence That Quinine Exhibits Antiviral Activity against SARS-CoV-2 ' 'Infection In Vitro', 'author': 'M Große', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': 'pone.0237480.ref016', 'first-page': '493', 'article-title': 'A simple method of estimating fifty percent endpoints', 'author': 'LJ Reed', 'year': '1938', 'journal-title': 'Am J Hyg'}, { 'key': 'pone.0237480.ref017', 'doi-asserted-by': 'crossref', 'DOI': '10.2807/1560-7917.ES.2020.25.3.2000045', 'article-title': 'Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR', 'volume': '25', 'author': 'VM Corman', 'year': '2020', 'journal-title': 'Euro Surveill'}, { 'key': 'pone.0237480.ref018', 'doi-asserted-by': 'crossref', 'first-page': '933', 'DOI': '10.1073/pnas.57.4.933', 'article-title': 'Recovery in tracheal organ cultures of novel viruses from patients with ' 'respiratory disease', 'volume': '57', 'author': 'K McIntosh', 'year': '1967', 'journal-title': 'Proc Natl Acad Sci U.S.A'}, { 'key': 'pone.0237480.ref019', 'article-title': 'Clinical and immunological assessment of asymptomatic SARS-CoV-2 ' 'infections', 'author': 'Q-X Long', 'year': '2020', 'journal-title': 'Nat Med'}, { 'key': 'pone.0237480.ref020', 'article-title': 'Novel SARS-CoV-2 specific antibody and neutralization assays reveal ' 'wide range of humoral immune response during COVID-19', 'author': 'M Dogan', 'year': '2020', 'journal-title': 'medRxiv'}], 'container-title': 'PLOS ONE', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0237480', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T18:34:39Z', 'timestamp': 1613586879000}, 'score': 1, 'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0237480'}}, 'subtitle': [], 'editor': [{'given': 'Stephen J.', 'family': 'Polyak', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 17]]}, 'references-count': 20, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2021, 2, 17]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0237480', 'relation': {}, 'ISSN': ['1932-6203'], 'subject': [], 'container-title-short': 'PLoS ONE', 'published': {'date-parts': [[2021, 2, 17]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit